Home › Research › Risk genes beyond APOE
The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset
Haiyan Liu, Thomas W. Marsh, Xinyu Shi, Alan Edward Renton, Kevin M. Bowling, Ellen Ziegemeier, Guoqiao Wang, Yuchen Cao et al.. Brain, 2025-02-04
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
We present a comprehensive global analysis of genetic variants associated with autosomal-dominant Alzheimer's disease (ADAD). A total of 550 variants in the APP, PSEN1 and PSEN2 genes were identified, of which 279 were classified as pathogenic or likely pathogenic based on American College of Medical Genetics and Genomics and the Association for Molecular Pathology criteria, utilizing data from the Dominantly Inherited Alzheimer Network (DIAN), literature and public databases. Symptomatic age at onset (AAO) data were estimated for 227 of these variants, allowing detailed characterization of their frequency, pathogenicity and AAO. Importantly, 226 variants met eligibility criteria for inclusion in disease-modifying clinical trials. Furthermore, we demonstrated the predictive value of mean variant AAO and parental AAO in predicting symptomatic AAO, validated against converters who became symptomatic during follow-up in the DIAN Observational Study. This dataset provides critical insights into the global landscape of ADAD and reveals the genetic and AAO heterogeneity of ADAD variants while refining variant trial eligibility criteria.
What this study adds
Evidence grade: Low
The record lists 550 participants. This global analysis identified 550 variants in APP, PSEN1 and PSEN2 associated with autosomal-dominant Alzheimer's disease, classified 279 as pathogenic or likely pathogenic, and estimated age at onset for 227 variants. It also found that mean variant age at onset and parental age at onset help predict symptomatic onset, which may refine eligibility for disease-modifying clinical trials, but the study itself does not test a treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Liu, H., Marsh, T. W., Shi, X., Renton, A. E., Bowling, K. M., Ziegemeier, E., et al. (2025). The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset. Brain. https://doi.org/10.1093/brain/awaf038
Vancouver
Liu H, Marsh TW, Shi X, Renton AE, Bowling KM, Ziegemeier E, et al. The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset. Brain. 2025. doi:10.1093/brain/awaf038. PMID: 39903689.
BibTeX
@article{liu2025-39903689,
author = {Liu, Haiyan and Marsh, Thomas W. and Shi, Xinyu and Renton, Alan Edward and Bowling, Kevin M. and Ziegemeier, Ellen and Wang, Guoqiao and Cao, Yuchen and others},
title = {{The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset}},
journal = {Brain},
year = {2025},
doi = {10.1093/brain/awaf038},
pmid = {39903689},
url = {https://doi.org/10.1093/brain/awaf038}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We present a comprehensive global analysis of genetic variants associated with autosomal-dominant Alzheimer's disease (ADAD).
- Furthermore, we demonstrated the predictive value of mean variant AAO and parental AAO in predicting symptomatic AAO, validated against converters who became symptomatic during follow-up in the DIAN Observational Study.
Why it matters
This global analysis identified 550 variants in APP, PSEN1 and PSEN2 associated with autosomal-dominant Alzheimer's disease, classified 279 as pathogenic or likely pathogenic, and estimated age at onset for 227 variants. It also found that mean variant age at onset and parental age at onset help predict symptomatic onset, which may refine eligibility for disease-modifying clinical trials, but the study itself does not test a treatment or cure.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Participants550
- Evidence strengthLow
How this study scored 57/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain) |
| Journal's citation record | 4 / 4 | Brain: journal h-index 503 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 550 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 21 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 11.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jorge J. Llibre‐Guerra: h-index 30 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 36 institution(s) in 10 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39903689) |
| Free to read | 2 / 2 | Free to read |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Risk genes beyond APOE from nearby years
Also in Risk genes beyond APOE
102 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.